Anjarium Biosciences AG, a biotech company in Schlieren (ZH) focused on creating and delivering a new class of non-viral gene therapies has closed a CHF55.5m Series A Financing.
The fast-growing Swiss e-mobility company EGO Movement (the GO AG) has agreed on a long-term strategic partnership with the leading Indian mobility group TVS Motor.
VISCHER completes to internal investigations in particularly sensitive industry sector.
Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through the acquisition of Metys Pharmaceuticals.
Polyphor and EnBiotix Inc., a privately held late clinical-stage rare disease company currently focused on products for rare, chronic respiratory diseases, have signed a merger agreement.
ombioxin SA, a clinical-stage biotechnology company based in Epalinges, Switzerland, entered into a worldwide licensing agreement with Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX), a fully integrated pharmaceutical company based in Woodcliff Lake, NY, USA.
Instem plc, a leading provider of IT solutions and services to the global life sciences market, has acquired its Swiss competitor PDS Pathology Data Systems AG, with offices in the United States and Japan, at an enterprise value of CHF 14.25m.
The VISCHER Dispute Resolution team led by Thomas Weibel successfully defended a Swiss bank in a multi-front battle.
The VISCHER dispute resolution team successfully enforced an ICC arbitral award rendered in London and stemming from international commodity trading in Switzerland.
The shareholders of the evitria Group have sold the evitria Group to Atlas Antibodies, Sweden. The transaction was completed on August 5, 2021.